Close Menu

New York State Department of Health

MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.

The company will now be able to market the test, which algorithmically weighs molecular markers and clinical information, in all 50 US states.